Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ENA 2020

24 - 25 Oct 2020
Online, Online, United Kingdom
Big data, machine learning and drug discovery in oncology
Prof Bissan Al-Lazikani - Institute of Cancer Research, London, UK
Big data, machine learning and drug discovery in oncology ( Prof Bissan Al-Lazikani -  Institute of Cancer Research, London, UK )
18 Dec 2020
Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells
Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom
Targeting a KRAS neoantigen peptide vaccine to DNGR-1  dendritic cells ( Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom )
27 Nov 2020
Using circulating tumour DNA dynamics to predict outcomes in advanced cancers
Dr Mohamed Gouda - The University of Texas MD Anderson Cancer Center, Houston, U...
Using circulating tumour DNA dynamics to predict outcomes in advanced cancers ( Dr Mohamed Gouda - The University of Texas MD Anderson Cancer Center, Houston, USA )
23 Nov 2020
Interim results from a phase 1/2 precision medicine study of PLX8394- a next gen...
Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor ( Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA )
17 Nov 2020
VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
4 Nov 2020
Prospective validation of single mouse testing by the paediatric preclinical tes...
Dr Peter Houghton - Greehey Children's Cancer Institute, San Antonio, USA
Prospective validation of single mouse testing by the paediatric preclinical testing consortium ( Dr Peter Houghton - Greehey Children's Cancer Institute, San Antonio, USA )
4 Nov 2020
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more...
Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients ( Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA )
4 Nov 2020
The ENA virtual meeting 2020
Dr. Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
The ENA virtual meeting 2020 ( Dr. Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
4 Nov 2020
Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation
Dr Pasi Janne - Dana Farber Cancer Institute, Boston, USA
Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation ( Dr Pasi Janne - Dana Farber Cancer Institute, Boston, USA )
4 Nov 2020
Development of novel inhibitors of KRASG12C
Dr Kevan Shokat - University of California San Francisco, San Francisco, USA
Development of novel inhibitors of KRASG12C ( Dr Kevan Shokat - University of California San Francisco, San Francisco, USA )
4 Nov 2020
Impact of angiotensin II pathway inhibition on tumour response to anti PD(L)1 ba...
Dr Julius Strauss - National Institutes of Health, Bethseda, USA
Impact of angiotensin II pathway inhibition on tumour response to anti PD(L)1 based therapy ( Dr Julius Strauss - National Institutes of Health, Bethseda, USA )
4 Nov 2020